Sciatica Therapy Tablet, Orally Disintegrating
FDA Label NDC 17312-021

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Trp Company for the product Sciatica Therapy (NDC 17312-021). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding otc - active ingredient, indications & usage, warnings, keep out of reach of children, otc - pregnancy or breast feeding, dosage & administration, other, inactive ingredient, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Keep Out Of Reach Of Children

Keep out of reach of children

Otc - Pregnancy Or Breast Feeding

If pregnant or breast-feeding, ask a health professional before use.

Other

Other information:

  • Active ingredients are micro-diluted in accordance with the Homeopathic Pharmacopoeia of the United States and are therefore non-toxic with no known side effects.
  • Store in a cool dark location.

Inactive Ingredient

Inactive Ingredients:
Advantol® 300, Lactose, Magnesium Stearate, Mannitol, Microcrystalline Cellulose.

* Please review the disclaimer below.